Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1517/14728214.2015.1031653 http://scihub22266oqcxt.onion/10.1517/14728214.2015.1031653 C5678969!5678969 !25826749     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25826749 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25826749 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Expert+Opin+Emerg+Drugs 2015 ; 20 (2 ): 313-29 Nephropedia Template TP {{tp|p=25826749 |t=2015. Emerging drugs for head and neck cancer |pdf=|usr=}}{{25826749 }} gab.com Text Emerging drugs for head and neck cancer JO: Expert Opin Emerg Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25826749 #FOAvip INTRODUCTION: Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, with chemotherapy or radiation improves overall survival. However, the response rates to cetuximab are modest. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve outcome. AREAS COVERED: Current EGFR-targeted drugs under clinical development include mAbs and tyrosine kinase inhibitors. The modest efficacy of these drugs implicates intrinsic or acquired resistance. Novel molecular agents inhibiting alternative targets to overcome anti-EGFR resistance in HNSCC are under investigation. Gene therapy and immunotherapy are also promising strategies to improve efficacy and reduce toxicity. EXPERT OPINION: To date, only six drugs have been FDA-approved for the treatment of head and neck cancer. Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression of EGFR in HNSCC tumors, clinical responses are limited. Genetic and epigenetic characterization of HNSCC tumors, coupled with improved preclinical models, should facilitate the development of more effective drugs. Twit Text FOAVip Emerging drugs for head and neck cancer ????Expert Opin Emerg Drugs http://www.kidney.de/pget.php?&tw=1&pmid=25826749 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25826749 #FOAvip English Wikipedia <ref>{{Cite pmid|25826749 }}</ref> Emerging drugs for head and neck cancer #MMPMID25826749 Wen Y ; Grandis JR Expert Opin Emerg Drugs 2015[Jun]; 20 (2 ): 313-29 PMID25826749 show ga INTRODUCTION: Despite improvements in treatment, survival rates of head and neck squamous cell carcinoma (HNSCC) are stagnant. The existing chemotherapeutic agents are non-selective and associated with toxicities. Combinations of the only the US FDA-approved epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, with chemotherapy or radiation improves overall survival. However, the response rates to cetuximab are modest. Thus, there is an urgent need for new agents that can be safely integrated into current treatment regimens to improve outcome. AREAS COVERED: Current EGFR-targeted drugs under clinical development include mAbs and tyrosine kinase inhibitors. The modest efficacy of these drugs implicates intrinsic or acquired resistance. Novel molecular agents inhibiting alternative targets to overcome anti-EGFR resistance in HNSCC are under investigation. Gene therapy and immunotherapy are also promising strategies to improve efficacy and reduce toxicity. EXPERT OPINION: To date, only six drugs have been FDA-approved for the treatment of head and neck cancer. Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression of EGFR in HNSCC tumors, clinical responses are limited. Genetic and epigenetic characterization of HNSCC tumors, coupled with improved preclinical models, should facilitate the development of more effective drugs. |Animals [MESH] |Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use [MESH] |Carcinoma, Squamous Cell/*drug therapy/genetics/pathology [MESH] |Drug Approval [MESH] |Drug Design [MESH] |Drug Resistance, Neoplasm [MESH] |Head and Neck Neoplasms/*drug therapy/genetics/pathology [MESH] |Humans [MESH] |Molecular Targeted Therapy [MESH]Emerging drugs for head and neck cancer (epmc).pdf DeepDyve Pubget Overpricing